$10 Million Worth of 7-OH Products Destroyed
/By Pat Anson
The Kansas City-based company that developed and launched the first 7-OH products destroyed $10 million worth of the concentrated kratom alkaloid this week, in anticipation of 7-OH soon being banned nationwide.
7-OH products made by CBD American Shaman have already been taken off the market in its home state, after Missouri’s attorney general sued the company, claiming its 7-OH tablets, gummies and shots are “deadly opioids” that pose significant risks. Several other states and dozens of cities and counties have also banned sales of 7-OH.
The DEA has begun the process of classifying concentrated 7-OH (7-hydroxymitragynine) as an illegal Schedule One controlled substance. The agency has already put the kratom alkaloid mitragynine pseudoindoxyl, along with the synthetic alkaloids MGM-15 and MGM-16, in that category.
In addition to 7-OH, American Shaman makes concentrated mitragynine pseudoindoxyl products, which are even more effective pain relievers than 7-OH.
“Unfortunately, of all the things, pseudoindoxyl is probably the very best pain medicine ever to hit earth,” Vince Sanders, Founder and CEO of American Shaman, told the Missouri Independent.
“I mean, very little mind change, very slow addictive properties, and just an incredible painkiller. But it’s gone. I’m sure it’ll show up as a pharmaceutical in five years or so, but as of now, people don’t have it available, which is truly a shame.”
The Department of Justice (DOJ) views pseudoindoxyl differently, calling it an “imminent hazard to public safety.”
“These are potent opioids being manufactured and sold in consumer products, often under labels that obscure their true risks. This action will protect our nation’s children and communities from the dangers of drug addiction and abuse,” Attorney General Todd Blanche said in a news release.
AKA Lawsuit
The DOJ’s news release makes a point of saying the agency has no desire to take natural leaf kratom off the market, and that it will “exercise enforcement discretion” by only targeting products that contain concentrated kratom alkaloids.
The American Kratom Association (AKA), which represents natural leaf kratom vendors, filed a lawsuit against the DEA and DOJ this week, seeking assurances that kratom leaf will be exempted from any federal bans.
In recent years, kratom vendors have lost a considerable amount of business to 7-OH competitors. The AKA has actively encouraged the federal government to go after 7-OH and similar products..
“The federal government made the right decision to target dangerous chemically manipulated opioid products,” says Mac Haddow, an AKA lobbyist and spokesman, “But that objective is undermined if legitimate natural kratom leaf products are swept into Schedule I because laboratories can now detect trace compounds at levels that do not present the public safety threat DEA sought to address.”
To be clear, kratom and its alkaloids are not traditional opioids derived from poppy plants. Kratom comes from the leaves of the Mitragyna speciosa tree in Southeast Asia, where it has been used for centuries as a natural stimulant and pain reliever.
Powdered kratom leaf gained in popularity in the United States nearly a decade ago, after many pain sufferers lost access to prescription opioids. The more potent 7-OH products went on the market in 2022 and quickly built up a following. Several million Americans have used kratom leaf or the concentrated kratom alkaloids, which have “opioid-like” effects but do not have the same risk factors as traditional opioids.
Norway 7-OH Death
In its scheduling order for 7-OH, the DEA claimed that “fatal overdoses involving 7-hydroxymitragynine have been reported,” but cited only one death. That lone case involved a middle-aged man in Norway who had a history of drug abuse and mental illness.
In addition to 7-OH and a “high concentration” of mitragynine, investigators found a sedative, antidepressant, and anti-seizure medication in the man’s blood and urine. Death was attributed to “intoxication by these substances.” Most overdoses blamed on 7-OH also involve other substances, making the cause of death unclear.
Undermining the DEA’s case against 7-OH even further is that the overdose in Norway occurred in 2014, long before 7-OH products appeared on the market.
7-OH advocates were successful in getting federal health officials to reopen and extend the public comment period on the scheduling of 7-OH until September 10th. That extension is not binding on the DEA, but it appears the agency has agreed to postpone any further scheduling action until additional public comments can be made and evaluated.
The original 30-day comment period received over 32,000 responses, one of the highest number of public comments ever recorded in the Federal Register.
